Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Afimetoran in Active Systemic Lupus Erythematosus
jRCT2011210069Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of afimetoran in systemic lupus erythematosus (SLE) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: SRI(4) response at Week 48. Started Apr 2022; status: recruiting.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2011210069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210069.